Compare iShares Core Growth Allocation ETF (AOR) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Biogen Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Biogen Inc trades at $204 (market cap $30.13B). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| AOR | BIIB | |
|---|---|---|
52-Week High | $70.12 | $216.63 |
52-Week Low | $62.26 | $128.93 |
Market Cap | — | $30.13B |
Sector | — | Health |
Enterprise Value | — | $37.20B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
